Section 2 - When to start treatment
European recommendations for initiation of ARV therapy
*Pay particular attention to drug-drug interactions, drug toxicities, immune reconstitution syndrome and adherence, etc.
EACS Guidelines, 2008. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf. Accessed March 11, 2009
When to start ART? Data from ART-CC
- Delaying ART to <350 (but not <375) cells/mm3 is associated with an increased risk of AIDS or death
Adapted from Sterne J, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 72LB.
D:A:D Study: CD4 count associatedwith risk of liver-related and othernon-AIDS related deaths.
- AIDS related: OIs or malignancies according to CDC definition of AIDS
- Liver-related: hepatic failure, HCC, OI or bleeding in pts with ESLD
Weber R et al. Arch Intern Med. 2006 166(15):1632-41
HOPS: median time to virological failure after suppression on HAART
Adapted from Uy JP, et al. 4th IAS 2007. Abstract WEPEB017
HOPS: causes of death by CD4 cell count at the start of HAART
Adapted from Palella FJ Jr, et al. JAIDS 2006;43:27–34